Free Newsletter
Senate hands FDA tobacco powers
Congratulations, FDA. You now have the dubious honor of regulating tobacco. Yesterday, the U.S. Senate gave its final stamp of approval to a bill that gives the agency power to regulate cigarettes and other tobacco products; President Obama is expected to sign it posthaste. Soon and very soon, the FDA will get the chance to wrangle with Big Tobacco.
The agency won't be able to ban nicotine, and it can't get rid of menthol immediately, either. But it can take aim at the hundreds of chemicals and toxins in cigarettes. The bill also heavily restricts tobacco marketing--an aspect of the measure that is expected to be challenged in court. Industry fees will help fund FDA oversight.
There are plenty of ways to debate this measure: Will FDA regulation lead people to think that cigarettes aren't dangerous? Does Phillip Morris's support of the legislation indicate that tobacco companies will somehow be able to turn it to their advantage? Will an already-stretched FDA be able to handle yet another charge from Congress? We've offered a few links below. Let us know what you think.
- read the New York Times story
- check out the article in Time
- get more from the Philadelphia Inquirer
Related Articles:
House votes to give FDA tobacco powers
FDA tobacco bill advances in Congress
New push for FDA power over tobacco
House votes to treat tobacco as a drug
Tobacco used to create new cancer vaccine
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





